Drug Names And Therapeutic Classes - NAPLEX

1. A 57-year-old male (weight 84 kg) comes to the pharmacy after a formulary update at his employer. Medical history: type 2 diabetes and established atherosclerotic cardiovascular disease. Allergies: none. Current medications: metformin ER 1000 mg PO daily, empagliflozin 10 mg PO daily, lisinopril 10 mg PO daily, rosuvastatin 20 mg PO nightly. Labs: A1c 8.2% (goal <7%), SCr 1.1 mg/dL (0.6–1.3), estimated creatinine clearance 78 mL/min. His plan will no longer cover semaglutide (Ozempic) and prefers another GLP-1 receptor agonist. Which medication should be substituted due to formulary restrictions?
   Answer: Liraglutide 1.8 mg subcutaneously once daily (GLP-1 receptor agonist) Understanding therapeutic alternatives within the same drug class enables appropriate formulary substitutions while maintaining clinical benefits, particularly for medications with proven cardiovascular outcomes. GLP-1 receptor agonists stimulate insulin secretion, suppress glucagon, and slow gastric emptying, with certain agents demonstrating cardiovascular benefit in patients with established ASCVD. Liraglutide (GLP-1 receptor agonist) should be substituted for semaglutide as both are GLP-1 agonists with proven cardiovascular benefits in patients with T2DM and ASCVD, making it the appropriate formulary alternative. Sitagliptin (DPP-4 inhibitor) works through a different mechanism and lacks cardiovascular outcome benefits, insulin glargine and its biosimilar Semglee are basal insulins that would represent a change in therapeutic approach rather than a formulary substitution within the same class. A clinical pearl is that among GLP-1 agonists, liraglutide, semaglutide, and dulaglutide have demonstrated cardiovascular benefits in outcome trials, making them interchangeable for patients with T2DM and ASCVD, though dosing frequency differs.
2. A 58-year-old woman (weight 69 kg) brings a prescription for prednisone 40 mg daily for 5 days and asks if it is the same as "prednisolone eye drops" she used previously. Medical history: asthma exacerbations. Allergies: none. Current medications: budesonide/formoterol 2 inhalations twice daily, albuterol HFA as needed, new prednisone 40 mg daily for 5 days. Labs: SCr 0.8 mg/dL (0.6–1.3), glucose 168 mg/dL (70–99). Which medication is a systemic corticosteroid (glucocorticoid) by therapeutic class?
   Answer: Prednisone 40 mg daily for 5 days Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for distinguishing systemic from local effects in corticosteroid use. The correct answer, prednisone 40 mg daily for 5 days, represents optimal pharmacist decision-making as it identifies the systemic glucocorticoid class for asthma exacerbations. Albuterol HFA and montelukast are incorrect as beta-agonist and leukotriene inhibitor classes, respectively. Ipratropium nasal spray is also incorrect because it is an anticholinergic for rhinitis, not systemic. A clinical pearl is that systemic corticosteroids can elevate glucose in short bursts. For similar questions, pharmacists should clarify route and class to address patient concerns.
3. A 50-year-old woman (weight 79 kg) with asthma is prescribed propranolol 40 mg twice daily for essential tremor. Medical history: asthma, essential tremor, anxiety. Allergies: none. Current medications: albuterol HFA 2 puffs every 4–6 hours as needed, fluticasone/salmeterol 1 inhalation twice daily, new propranolol 40 mg twice daily. Labs: SCr 0.9 mg/dL (0.6–1.3). Which medication is contraindicated or generally inappropriate for this patient based on therapeutic class and comorbidity?
   Answer: Propranolol 40 mg twice daily (nonselective beta-blocker) Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for assessing contraindications in patients with respiratory comorbidities. The correct answer, propranolol 40 mg twice daily (nonselective beta-blocker), represents optimal pharmacist decision-making as it is inappropriate in asthma due to bronchospasm risk. Albuterol HFA and fluticasone/salmeterol are incorrect as beta-2 agonist and ICS/LABA classes, beneficial for asthma. Primidone is also incorrect because it is an anticonvulsant, not directly contraindicated. A clinical pearl is that nonselective beta-blockers block beta-2 receptors, exacerbating asthma. In similar cases, pharmacists should recommend cardioselective beta-blockers like metoprolol.
4. A 28-year-old woman (weight 64 kg) who is 10 weeks pregnant asks about a new prescription for her blood pressure. Medical history: chronic hypertension, pregnancy. Allergies: none. Current medications: prenatal vitamin daily. New prescription: losartan 50 mg daily. Labs: SCr 0.7 mg/dL (0.6–1.3), K 4.2 mEq/L (3.5–5.0). Which medication is contraindicated for this patient based on therapeutic class in pregnancy?
   Answer: Losartan 50 mg daily (angiotensin II receptor blocker) Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for identifying fetal risks in pregnant patients with hypertension. The correct answer, losartan 50 mg daily (angiotensin II receptor blocker), represents optimal pharmacist decision-making as it is contraindicated in pregnancy due to teratogenicity. Labetalol and nifedipine ER are incorrect as beta-blocker and calcium channel blocker classes, safer in pregnancy. Methyldopa is also incorrect because it is a preferred central alpha-2 agonist for gestational hypertension. A clinical pearl is that ARBs can cause oligohydramnios and renal defects in fetuses. In similar decisions, pharmacists should consult ACOG guidelines for class safety in pregnancy.
5. A 72-year-old man (weight 70 kg) presents with new-onset muscle pain after starting a medication for a fungal nail infection. Medical history: hyperlipidemia, coronary artery disease. Allergies: none. Current medications: simvastatin 40 mg nightly, aspirin 81 mg daily, metoprolol tartrate 50 mg twice daily, and new terbinafine 250 mg daily started 2 weeks ago. Labs: AST 28 U/L (10–40), ALT 30 U/L (7–56), CK 980 U/L (30–200), SCr 1.1 mg/dL (0.6–1.3). Which medication is a statin (HMG-CoA reductase inhibitor)?
   Answer: Simvastatin 40 mg nightly Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for recognizing drug interactions and adverse effects like myopathy in hyperlipidemia treatment. The correct answer, simvastatin 40 mg nightly, represents optimal pharmacist decision-making as it identifies the statin class associated with elevated CK and muscle pain. Terbinafine and aspirin are incorrect as they are antifungal and antiplatelet classes, respectively, not linked to rhabdomyolysis. Metoprolol tartrate is also incorrect because it is a beta-blocker without direct muscle toxicity. A clinical pearl is that statins inhibit HMG-CoA reductase and can cause myopathy, especially with interacting drugs. In similar cases, pharmacists should verify class and monitor labs like CK to guide discontinuation or dose adjustments.
6. A 68-year-old male (weight 82 kg, height 178 cm) presents to the pharmacy for a refill and reports new dizziness and a heart rate of 52 beats/min at home. Medical history includes hypertension, atrial fibrillation, and benign prostatic hyperplasia. Allergies: penicillin (rash). Current medications: diltiazem ER 240 mg PO daily, metoprolol succinate 50 mg PO daily, apixaban 5 mg PO twice daily, tamsulosin 0.4 mg PO daily, and timolol 0.5% ophthalmic solution 1 drop OU twice daily (started 2 weeks ago for glaucoma). Labs: SCr 1.0 mg/dL (0.6–1.3), potassium 4.2 mEq/L (3.5–5.0), AST 22 U/L (10–40), ALT 25 U/L (7–56). Which medication is contraindicated for this patient based on therapeutic class?
   Answer: Timolol 0.5% ophthalmic solution 1 drop OU twice daily (nonselective beta-blocker) Understanding drug names and therapeutic classes is essential for identifying drug interactions and contraindications based on pharmacologic properties. Recognizing that medications from the same therapeutic class can have additive effects is crucial for preventing adverse events, particularly when systemic absorption occurs from topical formulations. Timolol ophthalmic solution (nonselective beta-blocker) is contraindicated because the patient is already taking metoprolol (beta-blocker) and diltiazem (rate-lowering calcium channel blocker), and the additive beta-blockade from systemically absorbed timolol is causing symptomatic bradycardia (HR 52 bpm). Tamsulosin (alpha-1 blocker) is appropriate for BPH and doesn't affect heart rate, apixaban (factor Xa inhibitor) is indicated for stroke prevention in atrial fibrillation, and diltiazem (non-dihydropyridine CCB) provides rate control but the combination with two beta-blockers is excessive. A clinical pearl is that ophthalmic beta-blockers can cause significant systemic effects including bradycardia, bronchospasm, and heart block, especially when combined with oral beta-blockers or other rate-lowering agents.
7. A 35-year-old woman (weight 66 kg) is prescribed metronidazole 500 mg twice daily for bacterial vaginosis but asks if it is "like metformin." Medical history: none significant. Allergies: none. Current medications: none. Labs: SCr 0.8 mg/dL (0.6–1.3), AST/ALT WNL. What is the therapeutic class of metronidazole?
   Answer: Nitroimidazole antibiotic/antiprotozoal Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for distinguishing antimicrobial from metabolic agents with similar names. The correct answer, nitroimidazole antibiotic/antiprotozoal, represents optimal pharmacist decision-making by classifying metronidazole for infections like bacterial vaginosis. Biguanide antihyperglycemic and macrolide antibiotic are incorrect as they describe metformin and erythromycin, respectively. Azole antifungal is also incorrect because it applies to fluconazole, not nitroimidazoles. A clinical pearl is that metronidazole can cause disulfiram-like reactions with alcohol. In similar confusions, pharmacists should counsel on class-specific warnings like avoiding alcohol.
8. A 30-year-old woman (weight 58 kg) is picking up a refill and asks if "Lamictal" is the same as "lamotrigine" because the tablets look different. Medical history: bipolar disorder. Allergies: none. Current medications: lamotrigine 200 mg daily, quetiapine 100 mg nightly, ethinyl estradiol/levonorgestrel 1 tablet daily. Labs: SCr 0.7 mg/dL (0.6–1.3), AST/ALT WNL. What is the primary indication for lamotrigine's drug class in this patient?
   Answer: Mood stabilization/antiepileptic therapy Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for confirming medication indications and preventing errors in psychiatric care. The correct answer, mood stabilization/antiepileptic therapy, represents optimal pharmacist decision-making as lamotrigine is used for bipolar disorder in this context. Acute bacterial sinusitis treatment and rapid relief of bronchospasm are incorrect as they refer to antibiotic and beta-agonist classes, not applicable here. Short-term insomnia treatment is also incorrect because it describes sedative-hypnotics like zolpidem, unlike lamotrigine's mechanism. A clinical pearl is that lamotrigine, an antiepileptic, requires slow titration to minimize rash risk in mood disorders. For similar queries, pharmacists should review patient history to align class with primary indication.
9. A 49-year-old man (weight 80 kg) is prescribed celecoxib 200 mg daily for arthritis pain and asks if it is "the same as Celexa." Medical history: osteoarthritis, depression. Allergies: none. Current medications: citalopram (Celexa) 20 mg daily, acetaminophen 1000 mg three times daily as needed, new celecoxib 200 mg daily. Labs: SCr 1.0 mg/dL (0.6–1.3). What is the therapeutic class of celecoxib?
   Answer: Selective COX-2 inhibitor NSAID Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for separating anti-inflammatory from antidepressant drugs with similar names. The correct answer, selective COX-2 inhibitor NSAID, represents optimal pharmacist decision-making by classifying celecoxib for arthritis. Selective serotonin reuptake inhibitor and opioid analgesic are incorrect as they describe citalopram and morphine, respectively. Corticosteroid is also incorrect because it applies to prednisone, not COX-2 inhibitors. A clinical pearl is that COX-2 inhibitors like celecoxib have lower GI risk but cardiovascular concerns. For similar queries, pharmacists should highlight class differences in indications and side effects.
10. A 46-year-old male (weight 88 kg) presents for a refill and says his insurance no longer covers his current inhaler. Medical history: COPD (GOLD group B) and hypertension. Allergies: none. Current medications: tiotropium (Spiriva HandiHaler) 18 mcg inhaled once daily, albuterol HFA 2 puffs every 4–6 hours as needed, and amlodipine 10 mg PO daily. Labs: SCr 0.8 mg/dL (0.6–1.3), potassium 4.0 mEq/L (3.5–5.0). The plan requires a formulary switch to another long-acting muscarinic antagonist (LAMA). Which medication should be substituted due to formulary restrictions?
    Answer: Umeclidinium 62.5 mcg inhaled once daily (LAMA) Understanding therapeutic equivalence within drug classes enables appropriate formulary substitutions while maintaining therapeutic efficacy. Long-acting muscarinic antagonists (LAMAs) block M3 receptors in airways, providing sustained bronchodilation for COPD management, and different LAMAs can be interchanged based on formulary requirements. Umeclidinium (LAMA) should be substituted for tiotropium as both are once-daily LAMAs with similar efficacy for COPD maintenance therapy. Ipratropium is a short-acting muscarinic antagonist (SAMA) requiring multiple daily doses and is not therapeutically equivalent to LAMAs, salmeterol is a long-acting beta-2 agonist (LABA) from a different therapeutic class that works through beta-receptor stimulation rather than muscarinic blockade, and montelukast is a leukotriene receptor antagonist with no established role in COPD management. A clinical pearl is that all LAMAs (tiotropium, umeclidinium, aclidinium, glycopyrrolate) have similar efficacy for COPD, allowing formulary interchanges, but dosing frequency varies (once or twice daily) depending on the specific agent.
11. A 40-year-old male (weight 76 kg) presents with a new prescription after an urgent care visit for nausea. Medical history: generalized anxiety disorder and opioid use disorder on maintenance therapy. Allergies: none. Current medications: buprenorphine/naloxone 8 mg/2 mg SL film twice daily, sertraline 100 mg PO daily, and hydroxyzine 25 mg PO at bedtime as needed. New prescription written: ondansetron 4 mg PO every 8 hours as needed for nausea. The pharmacy technician accidentally enters olanzapine 5 mg PO nightly due to a look-alike/sound-alike error. Labs: potassium 4.1 mEq/L (3.5–5.0), magnesium 2.0 mg/dL (1.7–2.2), QTc 440 ms. What is the therapeutic class of ondansetron?
    Answer: 5-HT3 receptor antagonist antiemetic Recognizing look-alike/sound-alike medications and understanding their different therapeutic classes prevents serious medication errors that could result in patient harm. Ondansetron and olanzapine are well-documented confused drug names that represent completely different therapeutic classes with distinct safety profiles and monitoring requirements. Ondansetron is a 5-HT3 receptor antagonist antiemetic that blocks serotonin receptors in the chemoreceptor trigger zone and is appropriate for treating nausea. The look-alike/sound-alike error with olanzapine (atypical antipsychotic) could cause serious harm as antipsychotics have significant metabolic, cardiovascular, and neurologic side effects, while benzodiazepines would cause sedation and potential respiratory depression with concurrent buprenorphine, and H2 antagonists treat acid-related disorders rather than nausea. A clinical pearl is that ondansetron can prolong QT interval, requiring caution in patients with baseline QTc prolongation or those taking other QT-prolonging medications, and maximum single dose should not exceed 16 mg due to cardiac risks.
12. A 63-year-old male (weight 90 kg) with chronic kidney disease presents with a new prescription for pain. Medical history: CKD stage 4, osteoarthritis, and hypertension. Allergies: none. Current medications: lisinopril 20 mg PO daily, hydrochlorothiazide 25 mg PO daily, acetaminophen 650 mg PO every 6 hours as needed (uses daily). New prescription: celecoxib 200 mg PO daily. Labs: SCr 2.6 mg/dL (0.6–1.3), estimated creatinine clearance 24 mL/min, potassium 5.1 mEq/L (3.5–5.0). Which medication is contraindicated for this patient based on therapeutic class due to risk of worsening kidney function and hyperkalemia when combined with current therapy?
    Answer: Celecoxib 200 mg PO daily (NSAID, COX-2 selective) Understanding therapeutic class contraindications based on organ function and drug interactions is essential for safe prescribing in special populations. NSAIDs, including COX-2 selective inhibitors, reduce prostaglandin synthesis, which can impair renal function and increase potassium retention, particularly when combined with ACE inhibitors. Celecoxib (COX-2 selective NSAID) is contraindicated due to the patient's advanced CKD (CrCl 24 mL/min), existing hyperkalemia (K+ 5.1 mEq/L), and concurrent ACE inhibitor use, as NSAIDs can precipitate acute kidney injury and dangerous hyperkalemia in this setting. Acetaminophen is the preferred analgesic in CKD as it doesn't affect renal function or potassium, hydrochlorothiazide may actually help lower potassium in this hyperkalemic patient, and lisinopril, while requiring monitoring in CKD, provides cardiovascular and renal protection when used carefully. A clinical pearl is that all NSAIDs, regardless of COX selectivity, should be avoided in patients with CrCl <30 mL/min, especially when combined with ACE inhibitors or ARBs due to risk of hyperkalemia and acute kidney injury.
13. A 60-year-old man (weight 102 kg) with type 2 diabetes is started on a new injectable medication and thinks it is insulin because it comes in a pen. Medical history: type 2 diabetes, obesity, hypertension. Allergies: none. Current medications: metformin 1000 mg twice daily, empagliflozin 25 mg daily, lisinopril 20 mg daily, and new semaglutide 0.25 mg subcutaneously once weekly. Labs: A1c 8.6%, SCr 1.0 mg/dL (0.6–1.3). Which medication is a GLP-1 receptor agonist?
    Answer: Semaglutide 0.25 mg subcutaneously once weekly Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for educating on injectable diabetes therapies and their distinct mechanisms. The correct answer, semaglutide 0.25 mg subcutaneously once weekly, represents optimal pharmacist decision-making as it identifies the GLP-1 receptor agonist class. Empagliflozin and metformin are incorrect as SGLT2 inhibitor and biguanide classes, respectively. Insulin lispro is also incorrect because it is a rapid-acting insulin, not a GLP-1 agonist. A clinical pearl is that GLP-1 agonists promote weight loss and cardiovascular benefits in diabetes. For similar cases, pharmacists should demonstrate injection technique and differentiate classes by administration frequency.
14. A 59-year-old man (weight 84 kg) with gout is told his plan will no longer cover colchicine capsules but will cover tablets. Medical history: gout, hypertension. Allergies: none. Current medications: colchicine 0.6 mg capsules twice daily for prophylaxis, allopurinol 300 mg daily, losartan 50 mg daily. Labs: SCr 1.2 mg/dL (0.6–1.3), uric acid 5.9 mg/dL (3.5–7.2). Which medication should be substituted due to formulary restrictions while maintaining the same drug (not a different class)?
    Answer: Colchicine 0.6 mg tablets twice daily Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for guiding formulary substitutions without altering therapy efficacy in gout management. The correct answer, colchicine 0.6 mg tablets twice daily, represents optimal pharmacist decision-making as it maintains the same anti-inflammatory drug for prophylaxis. Allopurinol and indomethacin are incorrect as they are xanthine oxidase inhibitor and NSAID classes, respectively. Prednisone is also incorrect because it is a corticosteroid, not a direct substitute for colchicine. A clinical pearl is that colchicine formulations may differ in bioavailability, requiring dose verification. For similar restrictions, pharmacists should prioritize same-drug switches before class alternatives.
15. A 68-year-old man (weight 92 kg, height 178 cm) presents to the pharmacy with dizziness and near-syncope after starting a "new heart pill." Medical history: heart failure with reduced ejection fraction, atrial fibrillation, hypertension, type 2 diabetes. Allergies: penicillin (rash). Current medications: carvedilol 25 mg twice daily, lisinopril 20 mg daily, furosemide 40 mg daily, spironolactone 25 mg daily, metformin 1000 mg twice daily, apixaban 5 mg twice daily, and a new prescription filled yesterday for verapamil ER 240 mg daily (patient thought it was "valsartan"). Labs: SCr 1.6 mg/dL (0.6–1.3), K 5.2 mEq/L (3.5–5.0), AST/ALT WNL. Which medication is contraindicated for this patient based on therapeutic class?
    Answer: Verapamil ER 240 mg daily (non-dihydropyridine calcium channel blocker) Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant as it allows pharmacists to assess contraindications, potential interactions, and patient-specific risks. The correct answer, verapamil ER (non-dihydropyridine calcium channel blocker), represents optimal pharmacist decision-making by identifying it as contraindicated in heart failure with reduced ejection fraction due to its negative inotropic effects. Valsartan, an angiotensin II receptor blocker, is incorrect as it is recommended for heart failure management, and amlodipine, a dihydropyridine calcium channel blocker, is not contraindicated in this setting. Metoprolol succinate, a beta-blocker, is also incorrect because it is a standard therapy for heart failure, unlike verapamil which exacerbates symptoms. A clinical pearl is that non-dihydropyridine calcium channel blockers should be avoided in systolic heart failure to prevent worsening cardiac output. When faced with similar decisions, pharmacists should review guidelines like ACC/AHA for class-specific contraindications in comorbidities.
16. A 70-year-old man (weight 76 kg) with COPD is prescribed a new inhaler and is confused between Spiriva and Symbicort. Medical history: COPD, hypertension. Allergies: none. Current medications: tiotropium (Spiriva Respimat) 2 inhalations once daily, albuterol HFA 2 puffs every 4–6 hours as needed, lisinopril 10 mg daily. Labs: SCr 1.0 mg/dL (0.6–1.3). Which medication is a long-acting muscarinic antagonist (LAMA)?
    Answer: Tiotropium (Spiriva) 2 inhalations once daily Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for differentiating inhalers and ensuring proper COPD control. The correct answer, tiotropium (Spiriva) 2 inhalations once daily, represents optimal pharmacist decision-making as it identifies the long-acting muscarinic antagonist class. Albuterol HFA and budesonide/formoterol are incorrect as short-acting beta-agonist and ICS/LABA classes, respectively. Fluticasone nasal spray is also incorrect because it is an intranasal corticosteroid for allergies. A clinical pearl is that LAMAs like tiotropium are foundational for COPD maintenance. In similar confusions, pharmacists should demonstrate device use and confirm class per GOLD guidelines.
17. A 54-year-old man (weight 91 kg) is prescribed allopurinol 300 mg daily and asks if it is "like alprazolam." Medical history: gout, anxiety. Allergies: none. Current medications: allopurinol 300 mg daily, colchicine 0.6 mg daily, alprazolam 0.25 mg three times daily as needed. Labs: uric acid 9.8 mg/dL (3.5–7.2), SCr 1.1 mg/dL (0.6–1.3). What is the therapeutic class of allopurinol?
    Answer: Xanthine oxidase inhibitor Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for differentiating urate-lowering from anxiolytic agents. The correct answer, xanthine oxidase inhibitor, represents optimal pharmacist decision-making by classifying allopurinol for gout. Benzodiazepine and uricosuric agent are incorrect as they describe alprazolam and probenecid, respectively. Nonsteroidal anti-inflammatory drug is also incorrect because it applies to ibuprofen, not allopurinol. A clinical pearl is that allopurinol requires HLA-B*5801 testing in high-risk populations for hypersensitivity. For similar confusions, pharmacists should counsel on class-specific monitoring like uric acid levels.
18. A 59-year-old male (weight 95 kg, height 175 cm) is discharged after a myocardial infarction and brings new prescriptions to the pharmacy. Medical history: type 2 diabetes, hyperlipidemia, coronary artery disease, and GERD. Allergies: none. Medication list: metformin 1000 mg PO twice daily, atorvastatin 80 mg PO nightly, pantoprazole 40 mg PO daily, and a new prescription for Brilinta 90 mg PO twice daily plus aspirin 81 mg PO daily. Labs: A1c 7.4% (goal <7%), SCr 0.9 mg/dL (0.6–1.3), platelets 210 $x10^3$/mcL (150–400). The patient asks what Brilinta is for. What is the primary indication for this drug class (ticagrelor, a P2Y12 inhibitor)?
    Answer: Secondary prevention of atherothrombotic events after acute coronary syndrome Understanding therapeutic classes and their primary indications ensures appropriate medication use and patient education about treatment goals. P2Y12 inhibitors like ticagrelor (Brilinta) work by blocking platelet activation and aggregation, making them essential for preventing thrombotic events in high-risk cardiovascular patients. The primary indication for ticagrelor is secondary prevention of atherothrombotic events after acute coronary syndrome (ACS), where dual antiplatelet therapy with aspirin reduces the risk of subsequent MI, stroke, and cardiovascular death. Treatment of acute ischemic stroke requires thrombolytics or mechanical thrombectomy rather than antiplatelet therapy, chronic stable angina requires anti-anginal medications like beta-blockers or nitrates as first-line therapy, and VTE prevention after orthopedic surgery typically uses anticoagulants rather than antiplatelet agents. A clinical pearl is that P2Y12 inhibitors must be used with aspirin (dual antiplatelet therapy) for ACS management, and the duration depends on bleeding risk versus ischemic risk assessment.
19. A 63-year-old woman (weight 60 kg) brings in two bottles: hydralazine 25 mg three times daily and hydroxyzine 25 mg three times daily as needed, stating she may have mixed them up. Medical history: hypertension, generalized anxiety, pruritus. Allergies: sulfonamides (hives). Current medications: losartan 100 mg daily, hydralazine 25 mg three times daily, hydroxyzine 25 mg three times daily as needed, sertraline 50 mg daily. Labs: SCr 0.8 mg/dL (0.6–1.3), BP today 168/92 mmHg. Which drug requires counseling due to its therapeutic class causing sedation and anticholinergic effects?
    Answer: Hydroxyzine 25 mg three times daily as needed Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant to identify drugs with sedative or anticholinergic effects that require patient counseling. The correct answer, hydroxyzine 25 mg three times daily as needed, represents optimal pharmacist decision-making as it is an antihistamine with significant sedation and anticholinergic risks. Hydralazine and losartan are incorrect as they are vasodilator and angiotensin II receptor blocker classes for hypertension, without sedative effects. Sertraline is also incorrect because it is a selective serotonin reuptake inhibitor for anxiety, with minimal anticholinergic activity. A clinical pearl is that first-generation antihistamines like hydroxyzine can cause drowsiness, especially in older adults. For similar mix-ups, pharmacists should counsel on class-specific side effects and monitor for uncontrolled symptoms like hypertension.
20. A 61-year-old man (weight 90 kg) is prescribed tamsulosin 0.4 mg nightly for urinary symptoms and asks if it is the same as "tamoxifen." Medical history: benign prostatic hyperplasia, hypertension. Allergies: none. Current medications: tamsulosin 0.4 mg nightly, amlodipine 5 mg daily. Labs: SCr 1.0 mg/dL (0.6–1.3). What is the therapeutic class of tamsulosin?
    Answer: Selective alpha-1 adrenergic blocker Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for clarifying drug purposes and avoiding mix-ups with similar names. The correct answer, selective alpha-1 adrenergic blocker, represents optimal pharmacist decision-making by classifying tamsulosin for BPH symptoms. Selective estrogen receptor modulator and 5-alpha-reductase inhibitor are incorrect as they describe tamoxifen and finasteride, respectively. Antimuscarinic is also incorrect because it applies to oxybutynin for bladder issues. A clinical pearl is that alpha-1 blockers like tamsulosin can cause orthostasis, especially with antihypertensives. For similar queries, pharmacists should differentiate classes by indication and mechanism.

Start this quiz